CAJ | 학술논문

目的探讨晚期肝癌介入治疗综合措施,进一步提高临床疗效.方法对33例肝癌介入治疗晚期综合症状采取一系列治疗措施.21例行经皮股动脉药盒导管系统(PCS)植入术;出血应用凝血酶原复合物;肝性脑病应用支链氨基酸和颈精氨酸等综合措施.结果 21例PCS 术后留置管全部保持通畅.33例平均生存期20.1个月,2年生存率为36%.结论对肝癌介入治疗晚期采取一系列综合措施可延长患者生存期,提高生存质量,是肝癌介入治疗上一个新台阶.
목적탐토만기간암개입치료종합조시,진일보제고림상료효.방법대33례간암개입치료만기종합증상채취일계렬치료조시.21례행경피고동맥약합도관계통(PCS)식입술;출혈응용응혈매원복합물;간성뇌병응용지련안기산화경정안산등종합조시.결과 21례PCS 술후류치관전부보지통창.33례평균생존기20.1개월,2년생존솔위36%.결론대간암개입치료만기채취일계렬종합조시가연장환자생존기,제고생존질량,시간암개입치료상일개신태계.
Objective To evaluate the clinical efficacy of interventional therapy in the treatment of hepatocellular carcinoma (HCC). Methods Thirty-three patients with HCC were synthetically treated by systematic measures. Among them, percutaneous port-catheter system (PCS) implantation via the femoral artery was performed in 21 cases. Patients with haemorrhage were treated with prothrombin complex concentrate and fibroraas, and patients with hepatic encephalopathy by branched-chain amino acids and arginine. Results All indwelling catheters of PCS were patent and no catheter tip dislocations were observed. Of 33 patients with advanced HCC, the mean survival rate was 20.1 months and 12 (36%) patients survived more than 2 years.Conclusion Patients with advanced HCC were treated by synthetic measures. Survival was prolonged, quality of life was improved significantly, and the effectiveness of interventional therapy was further improved.